Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

IGF-1 LR3 - 1mg - Insulin Like Growth Factor

IGF‐1 LR3 – Advanced Research Peptide This product is not intended for weight loss, human consumption, or veterinary use. It is sold for research purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved. IGF‐1 LR3, a long-acting analog of Insulin-like Growth Factor 1 (IGF-1), is a versatile research peptide widely used in laboratory studies to investigate tissue growth, muscle repair, bone regeneration, and neuroprotection. Researchers use IGF‐1 LR3 1mg in preclinical models to explore cellular mechanisms of proliferation, differentiation, and survival. Musculoskeletal & Bone Research In musculoskeletal studies, IGF-1 peptides have been shown to accelerate muscle regeneration. Rat models demonstrate that IGF‐1 LR3 treatment post-injury promotes satellite cell proliferation, enhances muscle strength, and speeds recovery. Additionally, IGF‐1 administration in rats with bone fractures has been associated with improved bone formation and f

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

IGF‐1 LR3 – Advanced Research Peptide

This product is not intended for weight loss, human consumption, or veterinary use. It is sold for research purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved. IGF‐1 LR3, a long-acting analog of Insulin-like Growth Factor 1 (IGF-1), is a versatile research peptide widely used in laboratory studies to investigate tissue growth, muscle repair, bone regeneration, and neuroprotection. Researchers use IGF‐1 LR3 1mg in preclinical models to explore cellular mechanisms of proliferation, differentiation, and survival.

Musculoskeletal & Bone Research

In musculoskeletal studies, IGF-1 peptides have been shown to accelerate muscle regeneration. Rat models demonstrate that IGF‐1 LR3 treatment post-injury promotes satellite cell proliferation, enhances muscle strength, and speeds recovery. Additionally, IGF‐1 administration in rats with bone fractures has been associated with improved bone formation and faster healing, highlighting its potential in bone regeneration studies.

Neuroprotection & Cognitive Research

Research on IGF‐1 LR3 1mg peptide reveals neuroprotective benefits in rat models of brain injury. Administration of IGF‐1 peptides improves cognitive function and reduces neuronal damage, indicating potential applications in the study of neurodegenerative diseases and traumatic brain injury.

Synergistic Research Applications

IGF‐1 has been studied in combination with other growth factors, such as VEGF, to enhance tissue repair and angiogenesis. These findings suggest IGF-1 LR3 can be utilized in complex experimental designs investigating combinatory regenerative therapies.

Research Use & Compliance

All IGF-1 LR3 peptides sold on our platform are strictly for laboratory, analytical, or research purposes. This product is not intended for human or veterinary use, and all studies should comply with relevant research regulations and safety guidelines.

References:

Gawri, R., et al. “Synergistic Effect of IGF-1 and VEGF in Wound Healing.” Journal of Wound Care, vol. 26, no. 7, 2017, pp. 413-419. https://www.jwc.com/

Ma, X., et al. “The Role of IGF-1 in Bone Fracture Healing in Rats.” Bone Research, vol. 6, no. 1, 2018, pp. 15-24. https://www.boneresearchjournal.com/

Schwabe, C., et al. “Insulin-Like Growth Factor 1 and Muscle Regeneration in Rats.” Journal of Muscle Research and Cell Motility, vol. 21, no. 3, 2000, pp. 163-173. https://link.springer.com/

Xie, J., et al. “Neuroprotective Effects of IGF-1 in Traumatic Brain Injury in Rats.” Neuroscience Letters, vol. 551, 2013, pp. 11-16. https://www.journals.elsevier.com/neuroscience-letters

Zhu, X., et al. “IGF-1 and Its Role in Tissue Repair in Rat Models.” Endocrinology, vol. 159, no. 4, 2018, pp. 1527-1535. https://academic.oup.com/endo

NuScience Peptides sells research products only, they are not for human consumption.

Synonyms:

Insulin Like Growth Factor-1 LR3; IGF-1 Long R3; IGF-1 Long Arg3;

Somatomedin C analogue; Itropin

Peer-Reviewed Sources:

Musarò, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., & Rosenthal, N. (2001). Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature genetics, 27(2), 195-200. Wangsa-Wirawan, N. D., Colby, C. B., O’Neill, B. K., & Middelberg, A. P. J. (2000). The Characteristics of Protein Inclusion Bodies: Physicochemical Properties of an Insulin-like Growth Factor Analog-Long-R3-IGF-1. Tavakkol, A., Elder, J. T., Griffiths, C. E., Cooper, K. D., Talwar, H., Fisher, G. J., & Voorhees, J. J. (1992). Expression of growth hormone receptor, insulin-like growth factor 1 (IGF-1) and IGF-1 receptor mRNA and proteins in human skin. Journal of Investigative Dermatology, 99(3), 343-349. LeRoith, D., & Yakar, S. (2007). Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nature Clinical Practice Endocrinology & Metabolism, 3(3), 302-310. Berryman, D. E., Christiansen, J. S., Johannsson, G., Thorner, M. O., & Kopchick, J. J. (2008). Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Hormone & IGF Research, 18(6), 455-471. Francis, G. L., Ross, M., Ballard, F. J., Milner, S. J., Senn, C., McNeil, K. A., & Wells, J. R. E. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of molecular endocrinology, 8(3), 213-223. Ding, H. U., Gao, X. L., Hirschberg, R., Vadgama, J. V., & Kopple, J. D. (1996). Impaired actions of insulin-like growth factor 1 on protein Synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. Journal of Clinical Investigation, 97(4), 1064.

Connected topics

Follow this recovery question